Development and Research over time

Robust, clinically validated results to ensure patients get the care they deserve

A broad on-demand assay menu delivers reliable results across a wide range of applications, making test consolidation easy and effective

Roche has partnered with (RED) on a shared mission to bring awareness to the importance of diagnostics and testing in the global fight against HIV/AIDS through educational creative content.

Learn how the AVENIO Edge System is bringing automation to NGS Sample Prep

This year’s STEM Careers Day reached over 900 students from 6 high schools, inspiring what may become the next generation of STEM innovators in healthcare or biotech.

Nonalcoholic fatty liver disease (NAFLD) is a group of conditions that is characterized by the accumulation of excess fat in the liver that is not directly attributed to the consumption of alcohol.

The SARS-CoV-2 Rapid Antibody Test can be used to determine whether patients have already been infected with the virus. Learn how it works.

cobas® 6800/8800 Systems are included as part of the updated World Health Organization (WHO) policy guidelines on nucleic acid amplification tests (NAATs) to detect tuberculosis (TB) and drug-resistant TB. The new guidance expands the number of rapid molecular tests available to national TB programmes in high-burden countries, enabling multi-partner diagnostic approaches that can benefit patients and communities.

Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for anti-PD1 immunotherapy.

Since the first EU Quality Management System certificate (IVDR) was issued by our notified body, TÜV SÜD, in December 2020, all relevant Quality Management Systems have been successfully audited.

Roche today announced that its cobas® SARS-CoV-2 Test for use on the widely available, high-throughput cobas® 6800/8800 Systems has received Emergency Use Authorisation (EUA) from the U.S. Food and Drug Administration (FDA) for testing individuals without symptoms or reasons to suspect COVID-19.

Roche launches DISCOVERY Green HRP chromogen detection kit to expand immunohistochemistry multiplexing in cancer research